Incannex Healthcare: Is Life Better On Nasdaq?

Incannex Healthcare is planning to redomicile to the US in a move designed to access deeper pools of capital and increase the company’s long-term market valuation.

A newly formed company will become Incannex’s (IXHL) parent and issue shares on Nasdaq, in exchange for all Incannex’s existing common shares. The biotech company, which is currently dual-listed and based in Australia, will continue to focus on developing medicinal cannabis and psychedelic therapies.

In this interview, CEO Joel Latham discusses topics including:

  • How the redomiciling and Nasdaq listing will impact active clinical programmes;
  • What it will mean for future clinical development programmes;
  • How the move will affect operational strategy; and
  • The implications for the current shareholders.

More By This Author:

Digital Healthcare: Leveraging Data And AI
Losing The Capacity To Shock
Cultivated Meat – Engineering The Growth Of Alternative Meats
How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.